114980-23-3

Usage

Uses

Used in Pharmaceutical Research:
3,5-DIMETHOXY-THIOBENZAMIDE is used as a research compound for its potential applications in the development of new pharmaceuticals. Its unique chemical structure allows it to be a candidate for various drug discovery processes, including the synthesis of novel therapeutic agents.
Used in Chemical Synthesis:
In the chemical synthesis industry, 3,5-DIMETHOXY-THIOBENZAMIDE is used as a key intermediate or building block for the creation of more complex organic molecules. Its functional groups facilitate various reactions, making it a valuable component in the synthesis of specialty chemicals and materials.
Used in Academic Research:
3,5-DIMETHOXY-THIOBENZAMIDE is employed as a research tool in academic settings to study its chemical properties, reactivity, and potential interactions with other molecules. This helps in understanding its behavior in different chemical environments and its applicability in various fields of chemistry and biology.

InChI:InChI=1/C9H11NO2S/c1-11-7-3-6(9(10)13)4-8(5-7)12-2/h3-5H,1-2H3,(H2,10,13)

Upstream product

• 19179-31-8 3,5-dimethoxy-benzonitrile 
• 17213-58-0 3,5-dimethoxybenzamide 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 1132-21-4 3,5-dimethoxybenzoic acid 

Downstream Products

• 74466-84-5 N-[1-Dimethylamino-eth-(E)-ylidene]-3,5-dimethoxy-thiobenzamide 
• 1013621-95-8 2-(3,5-dimethoxyphenyl)thiazole-4,5-dione 
• 1186493-24-2 2-(3,5-dimethoxyphenyl)thiazole 
• 1221822-60-1 2-(3,5-dimethoxyphenyl)-4H-3,1-benzothiazine 
• 71565-97-4 C₁₀H₁₁N₃O₂ 
• 1333153-04-0 C₁₀H₁₃NO₂S 
• 1332459-45-6 C₁₄H₁₅NO₄S 
• 1332459-59-2 C₃₈H₅₂N₂O₇S₂ 
• 1097110-19-4 C₁₂H₁₁NO₄S 
• 74466-95-8 5-(3,5-Dimethoxy-phenyl)-3-methyl-[1,2,4]thiadiazole 
• 74466-91-4 5-(3,5-Dimethoxy-phenyl)-[1,2,4]thiadiazole 
• 74466-80-1 N-[1-Dimethylamino-meth-(E)-ylidene]-3,5-dimethoxy-thiobenzamide 

Relevant academic research and scientific papers

Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of liver toxicity by decreasing the lipophilicity, the middle phenyl of TAK-875 was replaced by 11 polar five-membered heteroaromatics. Subsequently, systematic exploration of SAR and application of molecular modeling, leads to the identification of compound 44, which was an excellent FFA1 agonist with robustly hypoglycemic effect both in normal and type 2 diabetic mice, low risks of hypoglycemia and liver toxicity even at the twice molar dose of TAK-875. Meanwhile, two important findings were noted. First, the methyl group in our thiazole series occupied a small hydrophobic subpocket which had no interactions with TAK-875. Furthermore, the agonistic activity revealed a good correlation with the dihedral angle between thiazole core and the terminal benzene ring. These results promote the understanding of ligand-binding pocket and might help to design more promising FFA1 agonists.

Synthesis and antibacterial activities of pleuromutilin derivatives with thiazole-5-carboxamide and thioether moiety

Seven novel pleuromutilin derivatives with thiazole-5-carboxamide and thioether moiety in the C14 side chain were designed and synthesised. The antibacterial activities of the target compounds were tested via agar-well diffusion method in vitro. The results showed that three target compounds still had antibacterial activity against Staphylococcus aureus ATCC26112 and Staphylococcus aureus SC at a low concentration of 0.05 μg mL-1.

NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g

Modulating reactivity and diverting selectivity in palladium-catalyzed heteroaromatic direct arylation through the use of a chloride activating/blocking group

(Chemical Equation Presented) Through the introduction of an aryl chloride substituent, the selectivity of palladium-catalyzed direct arylation may be diverted to provide alternative regioisomeric products in high yields. In cases where low reactivity is typically observed, the presence of the carbon-chlorine bond can serve to enhance reactivity and provide superior outcomes. From a strategic perspective, the C-Cl bond is easily introduced and can be employed in a variety of subsequent transformations to provide a wealth of highly functionalized heterocycles with minimal substrate preactivation. The impact of the C-Cl functional group on direct arylation reactivity has also been evaluated mechanistically, and the observed reactivity profiles correlate very well with that predicted by a concerted metalation-deprotonation pathway.

Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: Synthesis and structure-activity relationships

Neutrophils have an important role in the self-defense systems of organisms through the production of superoxide. On the other hand, it has been proposed that abnormal amounts of superoxide produced by neutrophils are a serious factor in tissue injury. A series of novel thiazole derivatives was prepared and evaluated inhibitory effect on superoxide production by human neutrophils in vitro. Among these compounds, 6-[2-(3,4- diethoxyphenyl)thiazol-4-yl]-pyridine-2-carboxylic acid (OPC-6535) was selected as one of the most promising compounds. The synthesis and structure- activity relationships of these compounds are reported herein.